Gallery
PM Modi visit USA
Only the mirror in my washroom and phone gallery see the crazy me : Sara Khan
Karnataka rain fury: Photos of flooded streets, uprooted trees
Cannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfit
Ranbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A Kiss
Oscars 2022: Every Academy Award Winner
Shane Warne (1969-2022): Australian cricket legend's life in pictures
Photos: What Russia's invasion of Ukraine looks like on the ground
Lata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'
PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
The Badminton Association of India (BAI) has announced a 14-member-strong India squad for
- Men’s Sr Hockey Nationals to be played in division-based format from April 4
- Mensik denies Djokovic 100th title in Miami final
- KIPG: Son of a vegetable vendor, Bihar’s Jhandu Kumar eyes Worlds, 2028 Paralympics
- Hardik Singh credits hard work and team unity for receiving HI Midfielder of the Year award
- Djokovic, Alcaraz land in same half of Miami draw
Only 311 of 1.9 mn Covaxin beneficiaries reported side effects: Govt Last Updated : 11 Mar 2021 07:28:45 PM IST 
Bharat Biotech's Covaxin has a negligible number of side effects reported among the beneficiaries of the Covid-19 vaccine, NITI Aayog's Member (Health), V.K. Paul said on Thursday.
"The vaccine has been administered so far to 19 lakh people and only 311 individuals of them have reported minimal side effects."It has stood the test of time with great safety," Paul said at a press briefing.The government also announced that Covaxin is now allowed for regular emergency use among the public.The licensure of Covaxin has been changed to emergency use authorisation from earlier approved restricted emergency use in clinical trial mode by India's drug regulatory authority.Calling the development good news, Paul said that now Covaxin is at the same level as the other vaccine authorised in India."It is a good news. This has taken the authorisation for Covaxin to the next level where Covishield has been operating," he said.Covishield, a Covid-19 vaccine developed by AstraZeneca and the Oxford University, is manufactured by Serum Institute of India (SII) here."It (Covaxin) was approved for REU but we scaled its authorisation under abundant precaution citing public interest. That restriction has been removed. Both the vaccines have the same intensity of licensure now," Paul added.A day ago, the Central Drugs Standard Control Organisation's Subject Expert Committee approved Covaxin for emergency use authorisation.Earlier, the vaccine's emergency use was permitted only in the clinical trial mode. This condition has now been waived off by the Drug Controller General of India (DCGI) now.The decision was taken after the expert panel studied the interim result of the Phase 3 trial of the vaccine which demonstrated 81 per cent efficacy.Bharat Biotech had announced results of Phase 3 clinical trials of Covaxin on March 3.IANS New Delhi For Latest Updates Please-
Join us on
Follow us on
What binds the two most talked about nations - India and Pakistan together? What makes the
Writer Smita Singh promises to bring a fresh twist to the horror genre with her latest pro
LG Electronics Inc said on Wednesday that it will introduce new C with its artificial inte
172.31.16.186
